Join Vatché Bartekian for a Featured Presentation on Quality-by-Design and Risk-Based Governance

September 23–24, 2026 | Courtyard Toronto Downtown | Toronto, Canada

Vantage BioTrials is pleased to announce that Vatché Bartekian, President, has been invited to speak at the 10th Operational Excellence in Clinical Trials Summit (OECT Summit Canada 2026), one of Canada’s leading conferences dedicated to advancing innovation and operational excellence in clinical research. The summit brings together leaders in Clinical Operations, Clinical Development, Project Management, Study Feasibility, Site Management, and Vendor Oversight to explore strategies that improve clinical trial performance.

Featured Presentation

Quality by Design Begins Before Study Start-Up: Embedding Risk-Based Governance into CRO and Vendor Selection

Quality-by-Design (QbD) is often associated with protocol development and study execution. However, one of the most important opportunities to improve trial quality occurs much earlier, during the selection of CROs and critical vendors.

In this presentation, Vatché will discuss how sponsors can strengthen study oversight by incorporating risk-based governance, quality expectations, and operational performance criteria into partner selection from the outset.

Key discussion topics include:

• Applying Quality-by-Design (QbD) before study start-up
• Risk-based approaches to CRO and vendor selection
• Strengthening sponsor oversight and governance
• Moving beyond cost-driven outsourcing decisions
• Building collaborative partnerships that improve trial quality

Why Attend This Session?

Whether you are planning your first clinical trial or managing a global development portfolio, this session will provide practical strategies for improving operational performance by making better decisions before a study begins.

Meet with Vantage BioTrials

Planning an upcoming clinical program?

Meet with Vatché and his team to discuss how Vantage BioTrials helps biotechnology, pharmaceutical, and medical device sponsors strengthen clinical trial execution through:

• Clinical Trial Management
• Quality-by-Design (QbD)
• Risk-Based Quality Management (RBQM)
• Clinical Operations Leadership
• Vendor Oversight
• Inspection Readiness
• Regulatory Compliance

Why Vantage BioTrials?

Vantage BioTrials partners with sponsors to transform clinical development strategies into successful clinical programs through disciplined execution, proactive risk management, and collaborative operational leadership.

Our experienced team works as an extension of sponsor organizations, helping identify and mitigate risks early while maintaining the highest standards of patient safety, regulatory compliance, and data integrity.

Schedule a Meeting

If you will be attending the 10th Operational Excellence in Clinical Trials Summit, we invite you to connect with Vatché to discuss your upcoming clinical development objectives.

info@vantagebiotrials.com

The post Operational Excellence in Clinical Trials Summit | September 23 – 24, 2026 first appeared on Vantage Biotrials.

Visit Us at Booth #22 and Join Our Executive Panel Discussion

October 7–8, 2026 | Sheraton Laval | Laval, Québec, Canada

Vantage BioTrials is proud to be a BIOHorizon 2026 Sponsor and Exhibitor (Booth #22). We are also pleased to announce that Vatché Bartekian, President, will moderate an executive panel discussion entitled:

From Clinical Strategy to Execution: Delivering Successful Clinical Programs

BIOHorizon is Québec’s flagship life sciences and health technologies event, bringing together biotechnology companies, pharmaceutical organizations, investors, researchers, healthcare leaders, and service providers to foster collaboration and business development.

Executive Panel Discussion

A successful clinical program requires more than a sound strategy, it requires disciplined execution.

Join Vatché and a panel of industry experts as they discuss practical approaches to transforming clinical strategy into successful execution through:

• Quality-by-Design (QbD)
• Risk-based clinical trial management
• Sponsor–CRO collaboration
• Operational excellence
• Lessons learned from real-world clinical programs

Visit Vantage BioTrials at Booth #22

Whether you’re preparing for your first clinical study or advancing a global development program, stop by Booth #22 to learn how Vantage BioTrials helps biotechnology, pharmaceutical, and medical device sponsors deliver successful early-late phase clinical trials through:

• Clinical Trial Management
• Quality-by-Design (QbD)
• Risk-Based Quality Management (RBQM)
• Clinical Operations Leadership
• Regulatory Compliance
• Inspection Readiness

Why Vantage BioTrials?

Vantage BioTrials partners with sponsors to transform clinical development strategies into successful clinical programs through disciplined execution, proactive risk management, and collaborative operational leadership.

Our experienced team works as an extension of sponsor organizations, helping identify and mitigate risks early while maintaining the highest standards of patient safety, regulatory compliance, and data integrity.

Let’s Connect at BIOHorizon

We look forward to meeting:

• Biotechnology companies
• Pharmaceutical sponsors
• Medical device and diagnostics innovators
• Radiopharmaceutical developers
• Investors and strategic partners

Visit Booth #22

Attend our panel discussion

Schedule a meeting: info@vantagebiotrials.com

About BIOHorizon

Organized by BIOQuébec and Montréal InVivo, BIOHorizon is Québec’s premier life sciences and health technologies conference. The 2026 event takes place October 7–8 at the Sheraton Laval, with an International Day on October 6, bringing together leaders from across Québec, Canada, and the global life sciences ecosystem.

The post BioHorizon | October 7 – 8, 2026 first appeared on Vantage Biotrials.

November 9–11, 2026 | Cologne, Germany

Vantage BioTrials is pleased to announce that Vatché Bartekian, President, will attend BIO-Europe 2026 in Cologne, Germany.

BIO-Europe is Europe’s largest and longest-running partnering conference for the global biotechnology and biopharmaceutical industry. The event is expected to bring together more than 5,800 participants representing over 3,200 companies from more than 60 countries.

If your organization is preparing for a Phase I–IV clinical trial, evaluating a clinical research organization or planning an upcoming clinical development milestone, Vatché welcomes the opportunity to discuss how Vantage BioTrials can support your program through disciplined execution, proactive risk management and collaborative clinical trial leadership.

Planning a clinical trial? Meet with Vantage BioTrials at BIO-Europe 2026 to discuss how our Quality-by-Design approach and structured operational oversight can help advance your development program.

Why Meet with Vantage BioTrials at BIO-Europe?

Selecting the right CRO involves more than outsourcing clinical trial activities. It requires a partner that can anticipate operational challenges, protect study quality and maintain clear oversight throughout the clinical development lifecycle.

Vantage BioTrials combines Quality-by-Design principles, risk-based quality management and experienced clinical operations leadership to help sponsors translate development strategies into practical and reliable trial execution.

Our collaborative operating model is designed to provide:

• Structured clinical trial governance
• Quality-by-Design implementation
• Proactive risk identification and mitigation
• Experienced project management and clinical monitoring
• Regulatory and ethics submission support
• Vendor oversight and performance management
• Inspection readiness and quality management
• Protection of patient safety and data integrity

Whether supporting an emerging biotechnology company entering clinical development or an established sponsor managing a complex multinational study, our team works as an extension of the sponsor organization and provides solutions aligned with the needs, risks and objectives of each program.

Who We Would Like to Meet

Vantage BioTrials welcomes discussions with:

• Biotechnology companies preparing for first-in-human or early-phase studies
• Pharmaceutical sponsors seeking responsive and experienced CRO support
• Medical device and diagnostic developers
• Radiopharmaceutical and nuclear medicine innovators
• Companies considering clinical development in Canada or North America
• Organizations planning multinational Phase I–IV programs
• Investors and strategic partners supporting clinical-stage companies

Clinical Trial Services and Expertise

Vantage BioTrials provides clinical trial management and operational oversight services across early- and late-phase development programs.

Our capabilities include:

• Clinical project management
• On-site and remote clinical monitoring
• Risk-Based Quality Management
• Site feasibility and selection
• Study start-up
• Regulatory and ethics submissions
• Site management and participant recruitment support
• Vendor oversight
• Trial Master File oversight
• Quality management and inspection readiness
• Medical device clinical studies
• Radiopharmaceutical and imaging-based trials
• Phase I–IV clinical development

Meet Vatché Bartekian

President, Vantage BioTrials

With more than 28 years of experience in the pharmaceutical and biotechnology sectors, Vatché Bartekian brings extensive expertise in global drug development and the operational execution of complex clinical programs.

His leadership emphasizes scientific integrity, proactive risk identification and mitigation, structured governance and disciplined trial execution.

At BIO-Europe 2026, Vatché looks forward to meeting with biotechnology and pharmaceutical executives to discuss:

• Clinical development strategy and operational planning
• Risk-based approaches to complex trial execution
• Canadian and North American clinical development opportunities
• Sponsor oversight and CRO governance
• Quality-by-Design implementation
• Medical device, diagnostic and radiopharmaceutical programs
• Early- through late-phase clinical trial support

Why Attend BIO-Europe 2026?

BIO-Europe is a leading global forum for biopharmaceutical partnering. The 2026 program is expanding beyond traditional business development and investment discussions to include clinical strategy, regulatory developments and manufacturing considerations.

The conference brings together biotechnology and pharmaceutical companies, investors, academic organizations and industry service providers for scheduled one-to-one meetings, educational sessions and strategic networking opportunities. Partnering meetings are facilitated through the partneringONE platform.

For clinical-stage companies, the event provides an opportunity to identify potential development partners, evaluate service providers and establish relationships that can support future clinical and commercial milestones.

Schedule a Meeting at BIO-Europe 2026

If you will be attending BIO-Europe 2026, we invite you to schedule a meeting with Vatché Bartekian.

We would welcome the opportunity to learn about your clinical development objectives and discuss how Vantage BioTrials may support your program through experienced leadership, proactive risk management and disciplined clinical trial execution.

Email: info@vantagebiotrials.com

About Vantage BioTrials

Vantage BioTrials is a Canadian clinical research organization specializing in clinical trial management, operational oversight, Quality-by-Design and proactive risk management.

We collaborate with biotechnology, pharmaceutical and medical device sponsors to support early-late phase clinical trials while maintaining rigorous standards of patient safety, regulatory compliance and data integrity.

The post BIO-Europe | November 9-11, 2026 first appeared on Vantage Biotrials.

April 20, 2026, Montréal, Canada – Vantage BioTrials, a leading Canadian Contract Research Organization (CRO) specializing in clinical trial management services, is proud to announce its participation in a strategic scientific collaboration with Sorintellis, Université de Montréal, Université Laval and IVADO.

The collaboration aims to advance a next-generation AI-powered clinical trial intelligence platform, TrialsBank, designed to improve clinical trial execution, patient outcomes and operational performance across global development programs.

AI-Powered Clinical Trial Intelligence to Improve Execution and Reduce Risk

As clinical trials become more complex, sponsors face increasing challenges related to clinical trial delays, data fragmentation and execution risk. While large volumes of data are generated, the ability to convert that data into actionable clinical insights remains limited.

TrialsBank addresses this gap by creating a structured clinical trial intelligence layer that enables:

• Real-time analysis of clinical trial data and operational metrics
• Early identification of clinical trial risks and performance gaps
• Predictive insights to improve clinical study timelines and efficiency
• Standardized frameworks for risk-based clinical trial management

This approach supports a transition from reactive trial management to proactive, intelligence-driven clinical operations.

Vantage BioTrials Strengthens Clinical Trial Execution Through AI and Risk-Based Oversight

As a CRO focused on inspection-ready clinical trial execution, Vantage BioTrials contributes deep expertise in translating data-driven insights into operational performance and measurable outcomes.

“Clinical trials do not fail due to a lack of data. They fail when risks are not identified early or managed effectively,” said Vatche Bartekian, President of Vantage BioTrials. “By integrating AI-powered intelligence with disciplined clinical trial execution, this collaboration has the potential to significantly improve study timelines, quality and overall success rates.”

Vantage BioTrials will support the initiative through its capabilities in:

• Risk-based monitoring (RBM) and proactive risk mitigation
• Clinical trial project management and operational oversight
• Quality-by-Design (QbD) implementation
• Regulatory-aligned, inspection-ready clinical trial delivery

“AI can generate insights, but clinical trial success ultimately depends on execution,” added Viken Bartekian, VP Corporate Development. “Our role is to ensure that these insights translate into aligned execution across sites, regions and programs, where performance is determined.”

Academic and AI Expertise Advancing Clinical Research Innovation

The collaboration leverages advanced research capabilities from Université de Montréal, Université Laval and IVADO to support:

• Machine learning models for clinical trial optimization
• Data standardization for multi-study clinical programs
• Scalable AI frameworks for clinical research analytics

Sorintellis leads the development of the TrialsBank platform, focusing on AI-driven solutions for clinical research and drug development.

What This Means for Sponsors and Clinical Development Programs

For biotechnology and pharmaceutical companies, this collaboration introduces a new approach to clinical trial performance management, enabling:

• Improved clinical trial timelines and milestone predictability
• Reduced operational and regulatory risk
• Enhanced data-driven decision-making in clinical development
• Greater consistency in multi-site and global clinical trials

This model aligns with evolving regulatory expectations, including ICH E6(R3), which emphasize risk-based quality management and continuous oversight throughout the clinical trial lifecycle.

About Vantage BioTrials

Vantage BioTrials is a Canadian-owned Contract Research Organization (CRO) that provides Phase I-IV clinical trial management services to the pharmaceutical, biotechnology and medical device industries. Known for its personalized service model, strategic value and commitment to quality, Vantage BioTrials uses innovative clinical trial management strategies focused on patient safety and the acceleration of new therapies to market. We offer a complete and integrated suite of full-service solutions designed to deliver operational efficiency at a competitive value across the life sciences sector.

Forward-Looking Statements

This press release contains forward-looking statements regarding the expected impact of AI-driven clinical trial intelligence and the TrialsBank platform. Actual results may vary based on technological, regulatory and operational factors.

The post Vantage BioTrials Joins AI Collaboration to Advance Clinical Trial Intelligence and Improve Trial Execution with TrialsBank™ first appeared on Vantage Biotrials.

April 20, 2026, Montréal, Canada – Vantage BioTrials, a leading Canadian Contract Research Organization (CRO) specializing in clinical trial management services, is proud to support CanReview, a pan-Canadian collaboration supported by the Accelerating Clinical Trials (ACT) Consortium to build a broadly accessible, Canada-wide single research ethics review system that will enable all research sites participating in a multi-site clinical trial to undergo one ethics review, while ensuring the highest ethical standards.

Collaborating with Research Ethics Boards, research teams, Indigenous community members, institutions and sponsors, patients and family partners, and many others, CanReview aims to enhance clinical trials efficiencies, increase Canada’s competitiveness, expand clinical trials to underserved, rural and remote locations, and promote equitable access to trial participation.

Supporting Faster, More Coordinated Clinical Trial Activation in Canada

As a Canadian CRO specializing in full-service clinical trial management, Vantage BioTrials is aligned with national initiatives aimed at improving collaboration between sponsors, CROs, institutions and regulatory bodies.

Through its participation in the CanReview partner network, Vantage BioTrials supports efforts to:

• Facilitate coordinated and harmonized REB submissions and approvals
• Enhance predictability in clinical trial start-up processes
• Strengthen Canada’s position as a competitive destination for global clinical trials

Aligned with Evolving Clinical Trial Regulatory and Operational Expectations

With increasing complexity in clinical development, early-stage coordination between stakeholders has become critical to minimizing delays and ensuring efficient trial execution.

Since its founding in 2007, Vantage BioTrials has focused on delivering disciplined clinical trial management, incorporating:

• Proactive operational oversight
• Risk-based quality management strategies
• Transparent communication across stakeholders

Participation in CanReview reflects the organization’s continued commitment to working within the national Canadian clinical trial framework to support more efficient and coordinated study start-up.

Advancing Canada’s Clinical Research Ecosystem

Canada continues to be recognized globally for its high-quality clinical research environment, strong regulatory framework and experienced clinical sites. Initiatives such as CanReview play an important role in ensuring that Canada remains competitive by improving the speed and coordination of trial activation.

By aligning with these national efforts, Vantage BioTrials continues to support sponsors in navigating the Canadian clinical trial landscape with greater efficiency, predictability and operational excellence.

About Vantage BioTrials

Vantage BioTrials is a Canadian-owned Contract Research Organization (CRO) that provides Phase I-IV clinical trial management services to the pharmaceutical, biotechnology and medical device industries. Known for its personalized service model, strategic value and commitment to quality, Vantage BioTrials uses innovative clinical trial management strategies focused on patient safety and the acceleration of new therapies to market. We offer a complete and integrated suite of full-service solutions designed to deliver operational efficiency at a competitive value across the life sciences sector.

About CanReview

CanReview is a pan-Canadian collaboration supported by the Accelerating Clinical Trials (ACT) Consortium to enable single research ethics review for multi-site clinical trials conducted across Canada, while ensuring the highest ethical standards. Collaborating with Research Ethics Boards, research teams, Indigenous community members, institutions and sponsors, patients and family partners and others, we are developing a system to enhance efficiencies and increase Canada’s competitiveness, expand clinical trials to underserved, rural and remote locations, and promote equitable access to trial participation. Together, we are building a Canada-wide ethics review system that benefits all people in Canada.

The post Vantage BioTrials Joins CanReview Partner Network to Support Faster Clinical Trial Start-Up in Canada first appeared on Vantage Biotrials.

Vantage BioTrials will attend the BioNJ BioPartnering Conference on May 12, 2026 in New Jersey, as part of the BioQuébec delegation.

This event brings together biotechnology companies, pharmaceutical organizations, investors, and service providers. It creates a valuable setting for collaboration and discussion across the life sciences ecosystem.

As clinical programs become more complex, early alignment between sponsors and CRO partners is increasingly important. As a result, strong operational planning and clear communication are essential for successful trial execution.

Representing Vantage BioTrials

Vatche Bartekian, President of Vantage BioTrials, will attend the conference.

As a member of BioQuébec, Vantage BioTrials is pleased to join the Québec delegation once again. This participation highlights the strength of Québec’s life sciences ecosystem and its growing role in global clinical research.

Full-Service Clinical Trial Management Expertise

Vantage BioTrials has supported sponsors for nearly two decades. Our model focuses on structured, full-service clinical trial management.

Our capabilities include:

• Clinical project management and oversight
• Risk-based monitoring
• Quality management systems
• Study start-up and site coordination
• Vendor oversight
• Management of complex and late-phase programs

In addition, our approach is grounded in Quality by Design (QbD) principles. It also includes proactive risk mitigation from the earliest stages of development. Therefore, potential challenges are identified early and managed effectively throughout the study.

Learn more about our therapeutic expertise.

Supporting Clinical Development in a Changing Landscape

Today, clinical development is evolving rapidly. Consequently, sponsors are looking for CRO partners who can provide both execution and strategic support.

At BioNJ, we look forward to discussing key topics such as:

• Managing complexity across clinical programs
• Supporting lean sponsor teams
• Maintaining data quality and patient safety
• Applying structured, risk-based approaches

These discussions are critical. They help ensure that promising therapies move forward efficiently while maintaining high standards.

About BioNJ BioPartnering

The BioNJ BioPartnering Conference is a leading life sciences event in the United States. It brings together innovators, investors, and partners to support collaboration and growth.

Learn more: https://www.bionj.org/

Connect with Vantage BioTrials

If you plan to attend BioNJ BioPartnering 2026, we would welcome the opportunity to connect.

We would be pleased to discuss how structured clinical trial management, proactive risk mitigation, and collaborative execution can support your development programs.

The post BioNJ BioPartnering | May 12, 2026 first appeared on Vantage Biotrials.

Vantage BioTrials will attend the Society of Nuclear Medicine and Molecular Imaging Annual Meeting (SNMMI 2026) from May 30 to June 2, 2026.

This global event brings together leaders in nuclear medicine, molecular imaging, and radiopharmaceutical development. It creates a space to share scientific advances and discuss real-world applications.

As innovation accelerates, clinical trial execution becomes more specialized. As a result, sponsors must rely on strong operational oversight and clear coordination.

Meet the Vantage BioTrials Team

Representing Vantage BioTrials at the meeting will be:

• Vatche Bartekian, President
• Viken Bartekian, Vice President, Corporate Development

They look forward to connecting with sponsors, investigators, and partners working in radiopharmaceutical and imaging-based development.

Radiopharmaceutical Clinical Trial Expertise

Radiopharmaceutical trials require a specialized operational approach. These studies involve complex logistics, strict regulatory expectations, and coordinated site execution.

At Vantage BioTrials, we support these programs through:

• Coordination with nuclear medicine teams and imaging sites
• Oversight of radiopharmaceutical handling and logistics
• Support for imaging endpoints and centralized review
• Risk-based monitoring tailored to complex protocols
• Collaboration with specialized clinical sites

In addition, our approach is grounded in Quality by Design (QbD). It also integrates proactive risk mitigation from the earliest stages. Therefore, teams can identify risks early and manage them throughout the trial lifecycle.

Learn more about our therapeutic expertise .

What We’re Focused On at SNMMI

Today, radiopharmaceutical development continues to evolve. Consequently, clinical programs require greater coordination and operational precision.

At SNMMI, we look forward to discussing:

• Managing complexity in radiopharmaceutical trials
• Coordinating imaging infrastructure and site readiness
• Maintaining data quality and protocol compliance
• Applying structured, risk-based oversight

These priorities are directly linked to successful execution. As a result, alignment between sponsors and CRO partners remains essential.

About SNMMI

The Society of Nuclear Medicine and Molecular Imaging Annual Meeting is a leading global conference in nuclear medicine and molecular imaging.

It brings together clinicians, researchers, and industry leaders. Together, they advance innovation across diagnostics and targeted therapies.

Learn more about the meeting: https://www.snmmi.org/

Connect with Vantage BioTrials

If you will be attending SNMMI 2026, we welcome the opportunity to connect.

We would be pleased to discuss how disciplined clinical trial management, proactive risk mitigation, and collaborative execution can support your radiopharmaceutical development programs.

The post SNMMI Annual Meeting | May 30 – June 2, 2026 first appeared on Vantage Biotrials.

Vantage BioTrials will be exhibiting at the New England Clinical Outsourcing Group (COG) conference on April 28–29, 2026 in Boston.

This event brings together clinical operations leaders, sponsors, and service providers from across the life sciences industry. It provides a practical forum to discuss the realities of clinical trial execution.

As clinical programs become more complex, these conversations are increasingly important. As a result, strong operational alignment and proactive planning are essential for successful outcomes.

Meet the Vantage BioTrials Team

Representing Vantage BioTrials at the conference will be Vatche Bartekian, President, and Viken Bartekian, VP or Corporate Development.

They look forward to connecting with sponsors and industry peers to exchange perspectives on clinical operations and trial execution.

Full-Service Clinical Trial Management Expertise

Vantage BioTrials brings nearly two decades of experience in clinical trial management. Our model focuses on structured execution, operational oversight, and quality-driven delivery.

Our capabilities include:

• Clinical project management and oversight
• Risk-based monitoring
• Quality management systems
• Study start-up and site coordination
• Vendor oversight and alignment
• Management of complex and late-phase programs

In addition, our approach is grounded in Quality by Design (QbD). It also incorporates proactive risk mitigation from the earliest stages of development. As a result, risks are identified early and managed throughout the trial lifecycle.

Learn more about our therapeutic expertise.

What We’re Focused on at COG

Today, sponsors face increasing pressure to deliver results efficiently while maintaining high standards of quality.

In this context, we look forward to discussing:

• Managing complexity across clinical programs
• Supporting lean sponsor teams
• Maintaining data quality and patient safety
• Applying structured, risk-based approaches

These topics are central to successful clinical trial execution. Therefore, open dialogue between sponsors and CRO partners remains essential.

About COG New England

The New England Clinical Outsourcing Group (COG) conference is a well-established event focused on clinical outsourcing and operations. It brings together industry stakeholders to share practical insights and best practices.

Learn more about the event: https://www.thepbcgroup.com/

Visit Us at Booth #5

If you will be attending COG New England, we welcome the opportunity to connect.

Visit Booth #5 to discuss how structured clinical trial management, proactive risk mitigation and collaborative execution can support your development programs.

The post COG New England | April 28–29, 2026 first appeared on Vantage Biotrials.

On Wednesday, April 22, our President, Vatche Bartekian, will serve as a panelist in the session: “How Can We Work with Study Sponsors and CROs to Get the Revenue We Deserve When We Deserve It?”

This discussion will focus on practical, solution-driven strategies to strengthen sponsor–CRO–site collaboration and improve the operational mechanics of fair, transparent, and timely site payments.

If you will be attending and would like to connect with Vantage BioTrials during the Forum, we welcome the opportunity to meet.

The post The Site Council Leadership Forum | April 21-22, 2026 first appeared on Vantage Biotrials.

Join us in Orlando, Florida, from February 2–5, 2026, as Vantage BioTrials brings its expertise in clinical trial management to the Summit for Clinical Operations Executives (SCOPE).

We’re excited to share key insights, connect with industry leaders, and explore innovative solutions shaping the future of clinical operations.

To discover how we can assist with your next clinical trial, please contact us at info@vantagebiotrials.com.

The post SCOPE Summit | February 2-5, 2026 first appeared on Vantage Biotrials.